In the field of multidrug resistance mediated by the multidrug transporter, P glycoprotein, which is encoded by the MDR-1 gene, our efforts continue to have a major focus on translational research, while trying to pursue basic investigations that have the potential for future clinical correlations. We have identified gene rearrangements as the mechanism responsible for the activation of MDR-1 in a large number of cell lines, and in patient samples. These rearrangements occur randomly and are characterized by the juxtaposition of a transcriptionally active gene 5' to MDR-1, thus avoiding disruption of MDR-1 structure. Our current efforts are directed at identifying the sites and mechanisms of gene rearrangement and we are currently directing efforts at identifying the breakpoints in these rearrangements. Our understanding of this process should be very valuable in furthering our understanding of the acquisition of drug resistance. While the occurrence of this phenomenon in clinical samples remains to be expanded, its demonstration in several samples from patients with refractory ALL, indicates this may be important in a defined group of patients, and our efforts are increasingly focused in this direction. Our efforts in this regard will be directed not only at identifying the frequency with which this phenomenon occurs clinically, but also efforts at understanding how this occurs and how it might be prevented. With regard to the latter we have preliminary studies ongoing examining the frequency with which this occurs as a function of the mode of drug administration. Specifically, we are seeking to answer whether administration as a bolus or as a continuous infusion can significantly affect the occurrence of chromosomal aberrations. These studies are being conducted in a primate model by looking at the frequency of chromosomal damage in normal bone marrow following the administration of either bolus or infusional drug. The drugs selected include VP-16, thiotepa and paclitaxel. To date data gathered using these three drugs shows a significant difference with less chromosomal damage seen following infusional therapy than following bolus administration. Our current investigations with MDR-1 arose out of studies which revealed a low frequency of acquired mutations in MDR-1. This prompted us to look at a other mechanisms of drug resistance for comparison. We began to actively pursue studies aimed at identifying non-Pgp mechanisms of paclitaxel resistance. Selections performed with paclitaxel in the presence of verapamil succeeded in isolating cell lines with acquired resistance to paclitaxel that did not over-express MDR 1. Characterization of these cells led to the identification of mutations in the predominant tubulin isotype, M40. Similar studies performed using two additional tubulin stabilizing agents, epothilone A and epothilone B, led to the isolation of drug resistant cells which were also shown to harbor mutations in beta tubulin. Using a refined molecular model of tubulin, and guided by the mutations identified in our drug resistant cell lines and the cross resistance profile of these cells, we were able to dock both paclitaxel and the epothilones in the putative binding pocket and propose a common pharmacophore for the taxanes, and the epothilones. The identification of the sites as distinct from those of other microtubule active agents, supports abundant pre-existing data, and provides excellent models to study the mechanism of paclitaxel and epothilone resistance, and the potential synergism of other agents in drug activity. We have also used these models to examine the role of p53 mutations in the acquisition of paclitaxel and epothilone resistance. Our studies indicate that the occurrence of a non-functional p53 early in the selection process is a universal finding, although the mechanism by which this occurs differ. We have also shown that p53 trafficks on microtubules and that nuclear accumulation following DNA damage requires both an intact microtubule network and motor proteins of the dynein family. Finally, we have been actively studying the expression of cell specific genes in endocrine neoplasms and how this might be potentially exploited in a gene therapy strategy. Studies with adrenal cancers and thyroid cancers indicate that expression of specific genes occurs in these cells, and that the expression of these genes can be modulated by the addition of differentiating agents which target the cAMP pathway, and novel agents that target histone deacetylases. These studies which arose out of our clinical trails in patients with adrenocortical cancer, are designed to find more specific and effective alternatives for the treatment of endocrine cancers, most of which are composed of very unique cells.
Showing the most recent 10 out of 15 publications
